Neurodegenerative Risk Module
Risk assessment for dementia/Alzheimer's disease
Key Facts
About New Amsterdam Genomics
Founded in 2021 and headquartered in Cambridge, Massachusetts, New Amsterdam Genomics is a private, AI-driven health technology company positioned at the intersection of genomics, bioinformatics, and clinical care. Its core offering is a proprietary AI platform that analyzes a customer's full genome alongside continuous scientific literature to provide personalized risk assessments and health recommendations directly to consumers, healthcare providers, and enterprises. The company claims a significantly higher rate of 'life-changing' reports compared to competitors by examining all ~22,000 genes and dynamically updating its analyses with new research, targeting major areas like cancer, cardiac health, chronic diseases, and medication optimization.
View full company profile